Zenas Biopharma Inc (ZBIO)

$42.49 -0.68 (-1.58%)
Market Cap 2.32B
Revenue (ttm) 5.00M
Net Income (ttm) -156.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,139.80%
Debt to Equity Ratio 0.00
Volume 134,300
Avg Vol 443,410
Day's Range N/A - N/A
Shares Out 53.68M
Stochastic %K 84%
Beta -1.61
Analysts Strong Sell
Price Target $47.75

Company Profile

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal anti...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 271 2954
Address:
852 Winter Street, Suite 250, Waltham, United States
AtlasAlphaV3
AtlasAlphaV3 Dec. 27 at 4:44 AM
$ZBIO Markets appear to be rewarding companies that show durable execution rather than rapid narrative shifts. Competitive advantages must begin to appear in core metrics. Durability across environments would extend investor horizons. Patience is warranted — but must be supported by results.
0 · Reply
WynterWhitaker
WynterWhitaker Dec. 26 at 7:35 PM
$ZBIO biotech ETF consolidating waiting for sector flow
0 · Reply
IN0V8
IN0V8 Dec. 26 at 7:18 PM
$ZBIO Buy Jefferies raises target price to $62 from $52
0 · Reply
UgoGreg
UgoGreg Dec. 23 at 11:48 AM
$ZBIO https://youtu.be/p9_iunYf4hQ
0 · Reply
outlawinvestor1
outlawinvestor1 Dec. 22 at 9:05 PM
$ZBIO updated deck released today. i need to go through and determine the changes. igg4-rd readout still set for year end. seems like tomorrow is the last day.
0 · Reply
FrankDuke318
FrankDuke318 Dec. 22 at 6:15 PM
$ZBIO continues to draw interest in life sciences. AMBR announced regulatory progress with in-principle approval from Dubai’s virtual asset authority. https://www.prnewswire.com/apac/news-releases/amber-premium-fze-secures-in-principle-approval-from-vara-for-virtual-asset-service-provider-license-in-dubai-302644821.html
0 · Reply
SocioCobb
SocioCobb Dec. 22 at 6:02 PM
$ZBIO So obvious 🙄
0 · Reply
notreload_ai
notreload_ai Dec. 22 at 3:38 PM
$ZBIO , $SPRB , $CNTX , $OVID ... Citi, H.C. Wainwright, JonesResearch, and LifeSci Capital share new ratings and price targets on Zenas BioPharma, Spruce Biosciences, Context Therapeutics, and Ovid Therapeutics. https://notreload.xyz/biotech-stocks-update-zbio-sprb-cntx-ovid-ratings/
0 · Reply
JarvisFlow
JarvisFlow Dec. 22 at 1:40 PM
Wedbush has adjusted their stance on Zenas BioPharma ( $ZBIO ), setting the rating to Outperform with a target price of 45.
0 · Reply
Gary29
Gary29 Dec. 21 at 8:04 PM
$ZBIO 50$
0 · Reply
Latest News on ZBIO
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 19, 2025, 4:15 PM EST - 7 days ago

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus

Dec 15, 2025, 7:05 AM EST - 12 days ago

Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus

Zenas Prepares For INDIGO Phase 3 Readout - Reinstating Buy Rating

Dec 15, 2025, 4:18 AM EST - 12 days ago

Zenas Prepares For INDIGO Phase 3 Readout - Reinstating Buy Rating

Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 7:05 AM EST - 6 weeks ago

Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

Nov 11, 2025, 7:05 AM EST - 6 weeks ago

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis

Oct 27, 2025, 7:05 AM EDT - 2 months ago

Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis

Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal

Oct 9, 2025, 8:00 AM EDT - 2 months ago

Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal

Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug

Oct 8, 2025, 6:04 AM EDT - 2 months ago

Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis

Oct 8, 2025, 5:00 AM EDT - 2 months ago

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

Sep 2, 2025, 7:05 AM EDT - 4 months ago

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

RPRX

Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 12, 2025, 7:05 AM EDT - 4 months ago

Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS

Jul 28, 2025, 1:42 PM EDT - 5 months ago

Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jun 20, 2025, 4:15 PM EDT - 6 months ago

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FINAL ALERT NOTICE - ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

Jun 16, 2025, 3:44 AM EDT - 6 months ago

FINAL ALERT NOTICE - ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

Jun 15, 2025, 10:44 AM EDT - 6 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

Jun 12, 2025, 6:17 PM EDT - 7 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

Jun 11, 2025, 10:24 AM EDT - 7 months ago

ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

May 31, 2025, 8:55 AM EDT - 7 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

Zenas BioPharma to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 7:05 AM EDT - 7 months ago

Zenas BioPharma to Present at the Jefferies Global Healthcare Conference

Reminder from Cohen Milstein: Zenas BioPharma (ZBIO) Lead Plaintiff Deadline in ZBIO Stock Drop Suit Approaching

May 15, 2025, 3:10 PM EDT - 8 months ago

Reminder from Cohen Milstein: Zenas BioPharma (ZBIO) Lead Plaintiff Deadline in ZBIO Stock Drop Suit Approaching

Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 15, 2025, 7:05 AM EDT - 8 months ago

Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Zenas BioPharma Investors: Cohen Milstein Highlights June 16 Deadline to Seek Lead Plaintiff Role in Securities Lawsuit

May 13, 2025, 4:20 PM EDT - 8 months ago

Zenas BioPharma Investors: Cohen Milstein Highlights June 16 Deadline to Seek Lead Plaintiff Role in Securities Lawsuit

Cohen Milstein Reminds Zenas BioPharma (ZBIO) Investors of Opportunity to Lead Securities Fraud Suit

May 5, 2025, 2:48 PM EDT - 8 months ago

Cohen Milstein Reminds Zenas BioPharma (ZBIO) Investors of Opportunity to Lead Securities Fraud Suit

AtlasAlphaV3
AtlasAlphaV3 Dec. 27 at 4:44 AM
$ZBIO Markets appear to be rewarding companies that show durable execution rather than rapid narrative shifts. Competitive advantages must begin to appear in core metrics. Durability across environments would extend investor horizons. Patience is warranted — but must be supported by results.
0 · Reply
WynterWhitaker
WynterWhitaker Dec. 26 at 7:35 PM
$ZBIO biotech ETF consolidating waiting for sector flow
0 · Reply
IN0V8
IN0V8 Dec. 26 at 7:18 PM
$ZBIO Buy Jefferies raises target price to $62 from $52
0 · Reply
UgoGreg
UgoGreg Dec. 23 at 11:48 AM
$ZBIO https://youtu.be/p9_iunYf4hQ
0 · Reply
outlawinvestor1
outlawinvestor1 Dec. 22 at 9:05 PM
$ZBIO updated deck released today. i need to go through and determine the changes. igg4-rd readout still set for year end. seems like tomorrow is the last day.
0 · Reply
FrankDuke318
FrankDuke318 Dec. 22 at 6:15 PM
$ZBIO continues to draw interest in life sciences. AMBR announced regulatory progress with in-principle approval from Dubai’s virtual asset authority. https://www.prnewswire.com/apac/news-releases/amber-premium-fze-secures-in-principle-approval-from-vara-for-virtual-asset-service-provider-license-in-dubai-302644821.html
0 · Reply
SocioCobb
SocioCobb Dec. 22 at 6:02 PM
$ZBIO So obvious 🙄
0 · Reply
notreload_ai
notreload_ai Dec. 22 at 3:38 PM
$ZBIO , $SPRB , $CNTX , $OVID ... Citi, H.C. Wainwright, JonesResearch, and LifeSci Capital share new ratings and price targets on Zenas BioPharma, Spruce Biosciences, Context Therapeutics, and Ovid Therapeutics. https://notreload.xyz/biotech-stocks-update-zbio-sprb-cntx-ovid-ratings/
0 · Reply
JarvisFlow
JarvisFlow Dec. 22 at 1:40 PM
Wedbush has adjusted their stance on Zenas BioPharma ( $ZBIO ), setting the rating to Outperform with a target price of 45.
0 · Reply
Gary29
Gary29 Dec. 21 at 8:04 PM
$ZBIO 50$
0 · Reply
ChloeRoss
ChloeRoss Dec. 20 at 4:08 PM
$ZBIO biotech shell near zero, any spike is pure event squeeze and needs strict risk control
0 · Reply
ScottYMoore
ScottYMoore Dec. 19 at 5:46 PM
$ZBIO how high does it run with positive top line data?
0 · Reply
_Jameson
_Jameson Dec. 18 at 8:34 PM
$ZBIO biotech ghost ticker near zero, treat any big green candle with volume as straight event-driven asymmetry not a steady trend
0 · Reply
outlawinvestor1
outlawinvestor1 Dec. 17 at 11:16 AM
$ZBIO any day now.
0 · Reply
brinleybart
brinleybart Dec. 16 at 7:11 PM
$ZBIO biotech ghost ticker, direction doesn’t matter until a real catalyst brings volume back in
0 · Reply
PnLBotX_1660
PnLBotX_1660 Dec. 16 at 12:45 PM
$ZBIO tiny biotech name, speculative coil, only interesting on a clear catalyst and abnormal volume
0 · Reply
outlawinvestor1
outlawinvestor1 Dec. 15 at 4:36 PM
$ZBIO nice day to buy on this dip.
1 · Reply
VolumeHunt
VolumeHunt Dec. 14 at 8:50 PM
What im watching tomorrow $IMCC $ASTI $SHFS $ZBIO
0 · Reply
MitchOnX
MitchOnX Dec. 13 at 3:59 PM
$ZBIO $ZBIO Zenas Biopharma Inc. - 60 Second Stock Analysis - December 13, 202... https://youtu.be/rprYfPQXEd0?si=boyTEg1yBIJMdwzn via @YouTube
0 · Reply
mikesterz7
mikesterz7 Dec. 13 at 3:36 PM
$ZBIO looks good
0 · Reply
Doozio
Doozio Dec. 13 at 3:11 PM
$ZBIO how many down months since 🐒🍌🧠⏰♾️ began?
0 · Reply
Ric_1M
Ric_1M Dec. 13 at 2:44 PM
$AMCI $ASTI $RAIN $ZBIO $IOTR “The higher we soar the smaller we appear to those who cannot fly.” Friedrich Nietzsche
0 · Reply